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3SUMMARY
The aim of this study was to review and describe indications for intraaortic balloon 
counterpulsation (IABP) use and identify the impact these have on outcomes at an 
Australian cardiothoracic tertiary referral hospital. A secondary aim was comparison of 
the Australian practice with a large multinational IABP data registry. Patient 
demographics, IABP indication, IABP complication rate and mortality in 662 patients 
treated with IABP at The Prince Charles Hospital (TPCH), Brisbane between January 
1994 and December 2004 inclusive were compared with The Benchmark 
Counterpulsation Outcomes Registry. Data were collected between 1994 and 2000 by 
retrospective patient record review and prospectively using the Benchmark database from 
2001 to 2004. Statistical analysis was undertaken using SAS (v8.2) software. The mean 
age of patients managed with IABP at TPCH (71.6% male) was 63.4 years (SD 12.4). In-
hospital mortality rate was 22% and the complication rate was 10.3%. TPCH indications 
for IABP were: weaning from cardiopulmonary bypass (34.2%); cardiogenic shock 
(24.4%); preoperative support (13%); catheter laboratory support (10.6%); refractory 
ventricular failure (7.3%); ischaemia related to intractable ventricular arrhythmias 
(4.5%); unstable refractory angina (4%); mechanical complications due to acute 
myocardial infarction (1.2%); and other (0.4%) (0.4% not reported). In comparison to 
Benchmark, IABP at TPCH demonstrated a prejudice toward intraoperative use (34.2% 
versus 16.6%; P=<0.0001) and an aversion to catheter laboratory support (10.6% versus 
19%; P=<0.0001). TPCH and Benchmark IABP outcomes demonstrated comparable 
mortality (22% versus 20.8%; P=ns) but increased TPCH complications (10.3% versus 
6.2%; P=<0.0001) owing to a 2% difference in observed insertion site bleeding.
4INTRODUCTION
Diastolic augmentation to assist in the treatment of left ventricular failure was described 
for the first time in 1958.1 Harken suggested that the rapid removal of blood from the 
femoral artery during systole and it’s replacement during diastole would assist cardiac 
output and unload the heart simultaneously.1, 2 Considering these principles an intraaortic 
balloon pump (IABP) prototype was developed in 1962 and integrated into patient care in 
1968.3, 4 Initial clinical experience was mixed; while an improvement in haemodynamic 
function was demonstrated, mortality rates were not significantly altered. Since 1968 
IABP development has continued and practice has consequently changed dramatically. 
IABP has progressed to become an established treatment widely used in the setting of 
cardiac failure and potential cardiac compromise. There have been major improvements 
in patient outcome as well as dramatic reductions in morbidity and mortality rates.5
Technological advance has allowed easier intraaortic balloon (IAB) catheter insertion, the 
provision of smaller catheters and a more efficient drive console resulting in greater 
circulatory benefits for the patient.6 Time has also seen a change in IABP indications. 
Traditionally indications for IABP have included cardiogenic shock, myocardial 
ischaemia, failure to separate from cardiopulmonary bypass and severe acute mitral 
regurgitation.7 The increasing use of IABP, however, has seen its scope evolve to include 
additional applications such as the provision of haemodynamic support during or after 
cardiac catheterisation, preoperative insertion in high risk patients, the treatment of 
refractory unstable angina, refractory ventricular failure and ischaemia related to 
intractable ventricular arrhythmias.8 Diversity of IABP use has also seen success in the 
5augmentation of cerebral blood flow in a setting of cerebral vasospasm, in the anaesthetic 
management of high risk cardiac patients undergoing non cardiac surgery, in the 
management of myocardial failure following  severe post partum haemorrhage and for 
circulatory support in septic shock.9-15
Papers demonstrate significant variance in practice between United States and non United 
States hospitals with differences in IABP utilisation rates, indications and outcomes.16
The purpose of this study was to review and describe current indications for IABP use 
and the impact these have on outcomes at an Australian cardiothoracic tertiary referral 
hospital. Recent establishment of large multinational registries containing data on IABP 
has afforded an opportunity for contrasting local practice.5, 8, 17, 18 A secondary aim of this 
study was the comparison of aspects of application and outcomes at The Prince Charles 
Hospital (TPCH) with those of a large multinational IABP data registry. To meet these 
aims this study set out to answer the following research questions:
1. What are the characteristics of TPCH IABP (including patient demographics 
and characteristics)?
2. What are the mortality and complication rates for IABP at TPCH?
3. Does IABP application and outcome significantly differ between TPCH and
The Benchmark Counterpulsation Outcome Registry?
6MATERIALS AND METHODS
Study patients and setting
TPCH is a 450 bed, metropolitan, government funded public, tertiary referral, teaching 
hospital, with a predominantly cardiothoracic medical and surgical case-mix. It 
incorporates a 16 bed coronary care unit, a dedicated 10 bed cardiac surgical intensive 
care unit (ICU) and an eight bed general ICU. Admission to the coronary care unit or 
either ICU depends upon the complexity of the patient condition and cardiological or 
surgical intervention. 
This study reports data related to 669 IABP catheter insertions in 662 patients. While 674
patients were managed with 683 consecutive IABP at TPCH between January 1, 1994
and December 31, 2004, data were unavailable for 12 patients (14 IABP insertions). All 
counterpulsation was employed using System 90, 90T, 97 or 98XT drive consoles and 
Datascope, Statgaurd, Profile 8 or Fidelity IABP catheters (8 French to 9.5 French). After 
obtaining both hospital and university ethical committee approval these patients were 
identified from the intensive care, cardiac surgical and cardiac catheter laboratory 
databases. Data were collected retrospectively from 1994 to 2000 and prospectively using 
the Benchmark Counterpulsation Outcomes Registry database from 2001 to 2004.
Individual patient hospital records were reviewed for missing data. Patients receiving an 
IABP at a referring institution prior to transfer and retaining this device upon TPCH 
admission were included in this study. Patient demographics, APACHE II score, 
admission diagnosis, co-morbidities, IABP indication, IABP complications, location of 
7catheter insertion, interventional cardiology and surgical procedures, mechanical 
ventilation, arrhythmia's, ICU outcome and hospital outcome were collected.
Classifications
IABP mortality was defined as an all-cause (any cause during or after IABP) in-hospital 
mortality. Insertion indications were: preoperative support in the high risk patient 
undergoing coronary artery bypass graft (requiring catheter insertion prior to aortic cross 
clamping); post cardiopulmonary bypass (intraoperative IAB catheter insertion and the 
commencement of IABP due to difficulties weaning the patient from cardiopulmonary 
bypass, or IABP during the recovery phase due to postcardiotomy failure); cardiogenic 
shock (ejection fraction < 40% combined with systolic blood pressure < 90mmHg for 
hour, unresponsive to fluid administration alone); catheter laboratory support (IAB 
catheter insertion in the catheter laboratory prior to or during a procedure); unstable 
refractory angina; refractory ventricular failure; ischaemia related to intractable 
ventricular arrhythmias; mechanical complications due to acute myocardial infarction; 
and other (indications not fitting the above counterpulsation indications). Complications
were: bleeding (IAB catheter insertion site bleeding and haematoma); balloon failure 
(IAB rupture, leak, poor inflation or poor augmentation); limb ischaemia; limb 
amputation; and balloon entrapment.
Statistical analysis and comparison
Patient demographics and characteristics were compared using chi square, Fisher’s exact 
(X2) and student’s t test with correction for multiple comparisons. Calculations were 
8performed using version 8.2 of the SAS software package. Wherever possible results 
were expressed as mean r standard deviation (SD). Data from TPCH were compared 
with data from The Benchmark Counterpulsation Outcomes Registry. (The Benchmark 
Counterpulsation Outcomes Registry is the largest IABP registry providing perpetual, 
prospective IABP data on patients treated at 260 hospitals in 18 countries. However, 
despite the involvement of 18 countries, the majority of data represents practice in the 
United States [85% of total patient enrolments] and to a lesser degree Europe [11% of 
total patient enrolments]).5 The comparative Benchmark Counterpulsation Outcomes 
Registry data were collected between 1996 (registry inception) and 2004 inclusive.
RESULTS
What are the characteristics of TPCH IABP (including patient demographics and 
characteristics)?
Baseline clinical characteristics for the total TPCH population and IABP indications are 
shown in Table 1. Participants were aged between 14 and 89 years. Of the 669 TPCH 
IABP cases, 599 were admitted to an ICU with a mean ICU length of stay of 99.8 hours
(SD 125.3; range 1-1252). Eighty five percent of IABP patients cared for in ICU received  
mechanical ventilation for a mean of 59.3 hours (SD 98.7). Of those IABP patients not 
admitted to an ICU, 64 were managed in the coronary care unit only while 6 died in the 
operating room. 
TAKE IN TABLE 1 HERE
9During the study period, 431 patients treated with IABP underwent cardiac surgery 
representing a 2.4% use rate of cardiac surgical IABP (17,785 cardiac surgical operations 
were performed between 1994 and 2004 at TPCH). IABP utilisation at TPCH increased 
by 572% from 1994 (22 insertions) to 2004 (126 insertions) (Figure 1).
TAKE IN FIGURE 1 HERE
IAB insertion was performed in the catheter laboratory (43.8%), the operating room 
(42.2%), the ICU or coronary care unit (10.4%), other hospitals (2.1%) and in other 
locations (0.9%) (not recorded: 0.6%). The predominant catheter size was 40 millilitre 
volume (43%). Fifty percent of catheters were sheathed while 31% were unsheathed 
(19% of cases were unrecorded). A percutaneous approach was used in 97% of cases 
with only one patient subject to a trans-aortic approach and three patients requiring 
placement with surgical cutdown (2.8% not recorded).
What are the mortality and complication rates for IABP at TPCH?
Total TPCH IABP in-hospital mortality was 22% with an overall ICU mortality of 
15.9%. Between 1994 and 2004 in-hospital mortality decreased while APACHE II scores 
increased (Figure 2). In this series the APACHE II score demonstrated a linear 
relationship with in-hospital mortality despite a predominance of cardiothoracic patients 
(Figure 3). Total TPCH complication rate was 10.3%. No limb amputation was required 
in the TPCH series. All IABP outcomes are shown in Table 2.
TAKE IN TABLE 2 HERE
TAKE IN FIGURE 2 HERE
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TAKE IN FIGURE 3 HERE
Does IABP application and outcome significantly differ between TPCH and The 
Benchmark Counterpulsation Outcome Registry?
The difference between TPCH and Benchmark IABP application and outcomes is shown 
in Tables 1 and 2. TPCH was more likely to utilise IABP than Benchmark in the setting 
of: weaning from cardiopulmonary bypass; cardiogenic shock; and ischaemia related to 
intractable ventricular arrhythmias. TPCH was less likely to utilise IABP than 
Benchmark in the setting of: catheter laboratory support; unstable refractory angina; and 
mechanical complications due to acute myocardial infarction. TPCH demonstrated 
greater survival rates than Benchmark in the setting of: weaning from cardiopulmonary 
bypass; refractory ventricular failure; and mechanical complications due to acute 
myocardial infarction. TPCH survival was poorer than Benchmark in the settings of 
preoperative support in the high risk patient undergoing coronary artery bypass surgery 
and ischaemia related to intractable ventricular arrhythmias. IABP complication rates 
were higher in the TPCH series than Benchmark owing to an increased rate of access site 
bleeding.
DISCUSSION
The pre-emptive use of IABP is gaining popularity.16 Beginning with preoperative 
support of high risk patients undergoing coronary artery bypass graft surgery, practice 
has developed to incorporate support during percutaneous coronary intervention as a 
principal IABP indication. The growing acceptance surrounding pre-emptive IABP and 
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earlier intervention in the course of patient illness has seen a dramatic increase in the 
overall use of the IABP. Use of the IABP at TPCH has increased by almost 600% 
between 1994 and 2004 (Figure 1). Despite TPCH increasing pre-emptive IABP use in 
the settings of catheter laboratory support and preoperative support over the 11 years, 
weaning from cardiopulmonary bypass remains the principal  indication. A comparison 
of IABP indications between TPCH and Benchmark found most to demonstrate statistical 
difference, significant clinical difference, however, lay only in two areas. In contrast to 
Benchmark, TPCH application of IABP was greater when weaning from 
cardiopulmonary bypass and fewer when supporting catheter laboratory procedures.
Many reasons have been proposed for variations in IABP practice including controversy 
concerning the indications for use and differing philosophies on management for specific 
clinical indications.19-21 Additionally IABP is still regarded and registered as a 
complication rather than a therapy.21 It is likely the variation between TPCH and 
Benchmark indications represents a lack of consensus on the indications for IABP use. 
Reflecting the change in IABP practice, TPCH – like The Benchmark Counterpulsation 
Outcomes Registry – has demonstrated a decrease in mortality rates as well as an 
increased use (Figure 1). Improvement in TPCH mortality was demonstrated despite an 
escalation in APACHE II scores (Figure 2). While the APACHE II score is a general 
severity of illness measure not originally calibrated for cardiac surgical patients, its 
predictive power has shown to be discriminatory.22-24 In this series the APACHE II score 
demonstrated a linear relationship with in-hospital mortality despite a predominance of 
cardiothoracic patients (Figure 3). Considering this, uniform application of a general 
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measure of patient acuity such as APACHE II instead of the Parsonnet score, may be 
appropriate in the cardiothoracic setting. 
Encouragingly, comparison of IABP outcomes between TPCH and Benchmark over this 
11 year series demonstrates an equivalence of in-hospital mortality. Examining mortality 
by indication, however, revealed TPCH to have a significantly lower mortality associated 
with weaning from cardiopulmonary bypass and a higher mortality in the setting of 
preoperative support. It is interesting to note TPCH intraoperative application is almost 
20% higher than that of Benchmark. While trends of TPCH practice over the past 11 
years indicate greater application of pre-emptive IABP, it is apparent TPCH practitioners 
are more likely to undertake IABP intraoperatively than preoperatively, suggesting the 
superior outcome for intra/postoperative patients in the TPCH series cannot readily be 
dismissed on the basis of excluding critically ill poorer surgical candidates. While it 
could be argued those TPCH patients receiving intra/postoperative IABP were of a lower 
acuity as they were stable enough preoperatively to not require IABP, patient 
characteristics in both TPCH and Benchmark series were similar indicating this was not 
the case (Table 1). Additionally, TPCH’s higher intraoperative application most likely 
reflects a reluctance to insert IABP pre-emptively in the surgical setting, necessitating 
employment following the surgery when difficulty arises with bypass separation. This 
interpretation would imply TPCH are inserting IABP later, into patients of greater acuity. 
One might consider TPCH to be a high end user of the IABP with frequent use leading to 
experienced practitioners. The importance of frequent use of the IABP and therefore 
experience with its use should not be underestimated.25 Recent research suggests a 
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volume outcome relationship with improved mortality at high volume centres.26 The
authors are unsure as to whether or not this has any impact upon mortality following 
cardiopulmonary bypass. 
While TPCH complication rate was 10.3%, no major complications were demonstrated. 
There was no mortality directly attributable to counterpulsation, no limb amputations and 
no peripheral thromboembolism complications. Additionally, overall complication rates 
reduced over time from 9% in 1994, to 3.9% in 2004 when TPCH insertion rates were at 
their highest. For the 11 year period, however, TPCH overall complications were 4.1% 
higher than those of the Benchmark Counterpulsation Outcomes Registry. While the 
incidence of IABP complications presented in recent experience is generally low,5, 8, 16, 18, 
25, 27 TPCH is not on its own reporting a rate in excess of 10%.27-29 It should be noted 
TPCH complication rates are comparable or lower to those of Benchmark in all 
complication aspects barring access site bleeding. The comparison of complications 
between institutions becomes problematic because the definition of what constitutes a 
complication involves some degree of subjectivity. While access site bleeding is a 
common complication, some studies fail to identify bleeding as a complication within 
their series, despite listing other IABP complications such as limb ischaemia as 
problematic.30 Complication rates will vary dramatically depending on selective 
reporting, or as is the case with access site bleeding, anticoagulation protocols. 
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Study limitations
Comparison between TPCH and The Benchmark Counterpulsation Outcomes Registry 
could be seen as potentially flawed. Owing to the voluntary nature of Benchmark 
Counterpulsation Outcomes Registry involvement, results may not be representative of 
the entire spectrum of clinical practice. Additionally, as could be expected with any large 
scale multinational registry, any site to site variation in personnel or resources allocated 
to the registry may impact upon the accuracy of some records. It must also be considered 
all data is observational and some TPCH data has been collected retrospectively. 
Furthermore, owing to the retrospective nature of this study, it is recognised comparison 
of IABP usage and outcomes for individual indications does not reflect overall 
management of that particular indication, but rather distribution of overall IABP use in 
relation to the indication.
Concluding remarks
The greatest use of pre-emptive IABP occurs within the United States.16 This impacts 
heavily upon the results of The Benchmark Counterpulsation Outcomes Registry with 
84.7% of contributing patients based in US centres. While this recent trend of pre-
emptive IABP has been adopted at TPCH, insertion following cardiopulmonary bypass 
remains high, while supportive use within the catheter laboratory is comparatively low. 
Despite the variance in IABP indication between TPCH and The Benchmark 
Counterpulsation Outcomes Registry, mortality – the primary treatment outcome – is 
comparable.
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TABLE 1: Baseline Clinical Characteristics and Counterpulsation Indication of Patients 
Treated With IABP.
Variable TPCH Benchmark P value
Total population (n) 669 38,606
Age, mean (SD), yrs 63.4 (12.4) 65.5 (12.2)
Proportion of women 28.4% 32.3%
Ejection fraction, mean (SD) 39.7 (17.2) 37.1 (16)
Prior myocardial infarction 31.8% 29.1%
History of diabetes 21.2% 23.6%
Prior sternotomy 14.5% 13.8%
Peripheral vascular disease 12.6% 10.2%
APACHE II score, mean (SD) 18.3 (7.4) n/a
IABP duration, hours, mean (SD) 46.3 (32.8) 59
ICU length of stay, mean (SD), hrs 99.8 (125.3) n/a
Hospital length of stay, mean (SD), days 18.9 (24.2) 15
Indication
      Weaning from cardiopulmonary bypass 34.2% 16.6% <0.0001
      Cardiogenic shock 24.4% 20.6% 0.02
      Preoperative support in high risk patient
            undergoing CABG 13% 14.9% ns
      Catheter laboratory support 10.6% 19% <0.0001
      Refractory ventricular failure 7.3% 6.9% ns
      Ischaemia related to intractable 
            ventricular arrhythmias 4.5% 1.6% <0.0001
      Unstable refractory angina 4% 10.9% <0.0001
      Mechanical complications due to AMI 1.2% 5.7% <0.0001
      Other 0.4% 3% 0.0001
      Not reported 0.4%
Footnote: n/a = not available; ns = not significant.
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TABLE 2: IABP In-hospital Mortality by Counterpulsation Indication and Complication
Rates.
Assessment TPCH Benchmark P value
Total in-hospital mortality 22% 20.6% ns
      Weaning from cardiopulmonary bypass 15.7% 20% 0.005
      Cardiogenic shock 41.1% 37.7% ns
      Preoperative support in high risk patient
            undergoing CABG 12.6% 5.1% <0.0001
      Catheter laboratory support 8.5% 10% ns
      Refractory ventricular failure 16.3% 30.5% <0.0001
      Ischaemia related to intractable 
            ventricular arrhythmias 46.7% 24.9% <0.0001
      Unstable refractory angina 7.4% 7.8% ns
      Mechanical complications due to AMI 12.5% 26.1% <0.0001
Overall complication rate 10.3% 6.2% <0.0001
      Any access site bleeding 4.5% 2.5% 0.001
      Balloon failure 2.8% 2.9% ns
      Limb ischaemia 1.5% 2.7% 0.05
      Balloon entrapment 1% 1.1% ns
      Other 0.4% 1.2% ns
Footnote: ns = not significant.
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FIGURE 1: TPCH IABP Cases and In-hospital Mortality by Year.
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FIGURE 2: TPCH IABP In-hospital Mortality Versus Mean APACHE II Score by Year. 
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FIGURE 3: TPCH IABP In-hospital Mortality Versus APACHE II Score.
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Footnote: Mortality for the APACHE II groups 0-4 and 5-8 constituted three patients 
only. All died in ICU shortly following admission and received low scores due to a lack 
of physiological data.
